BREATHTEK UBT FOR H. PYLORI KIT AND PEDIATRIC UREA HYDROLYSIS RATE CALCULATION APPLICATION (PUHR-CA), VERSION 1.0

Test, Urea Adult And Pediatric (breath),

FDA Premarket Approval P100025

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the breathtek ubt for h. Pylori kit (breathtek ubt kit) and pediatric urea hydrolysis rate calculation application (puhr-ca), version 1. 0. The breathtek ubt kit is currently cleared for use inadult patients under 510(k) premarket notification, k014225, and the pranactin-citric is approved under nda 20-586/s-004. This device is indicated for: the breathtek ubt for h pylori kit (breathtek ubt kit) is intended for use in the qualitative detection of urease associated with h. Pylori in the human stomach and is indicated as an aid in the initial diagnosis and post-treatment monitoring of h. Pylori infection in adults, and pediatric patients 3 to 17 years old. The test may be used formonitoring treatment if used at 4 weeks following completion of therapy. For these purposes, the system utilizes an infrared spectrophotometer for the measurement of the ratio of 13co2 to 12co2 in breath samples, in clinical laboratories and point-of-care settings. The pediatric urea hydrolysis rate calculation application (puhr-ca), provided as a web-based calculation program, is required to obtain pediatric test results. The breathtek ubt kit is foradministration by a health care professional, as prescribed by a physician.

DeviceBREATHTEK UBT FOR H. PYLORI KIT AND PEDIATRIC UREA HYDROLYSIS RATE CALCULATION APPLICATION (PUHR-CA), VERSION 1.0
Classification NameTest, Urea Adult And Pediatric (breath),
Generic NameTest, Urea Adult And Pediatric (breath),
ApplicantOTSUKA AMERICA PHARMACEUTICAL, INC.
Date Received2010-06-22
Decision Date2012-02-22
Notice Date2012-03-07
PMAP100025
SupplementS
Product CodeOZA
Docket Number12M-0207
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product Yes
Applicant Address OTSUKA AMERICA PHARMACEUTICAL, INC. 2440 Research Blvd. rockville, MD 20850
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P100025Original Filing
S014 2019-08-12 Normal 180 Day Track No User Fee
S013 2018-04-20 30-day Notice
S012 2017-01-09 Real-time Process
S011 2016-12-06 30-day Notice
S010 2015-09-15 Normal 180 Day Track
S009 2015-07-16 Normal 180 Day Track
S008 2015-01-13 Normal 180 Day Track
S007 2014-08-08 Normal 180 Day Track
S006 2014-01-22 Special (immediate Track)
S005 2013-06-28 Normal 180 Day Track
S004 2013-02-01 Normal 180 Day Track
S003 2012-10-12 Special (immediate Track)
S002 2012-08-31 Normal 180 Day Track No User Fee
S001 2012-03-19 Normal 180 Day Track

NIH GUDID Devices

Device IDPMASupp
00857335005077 P100025 000
00857335005015 P100025 000
00857335005008 P100025 000
00840733101458 P100025 000
00840733101434 P100025 000

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.